Branched oligonucleotides (b-oligonucleotides) based on a novel branching monomer were used for site-specific sequence alteration in vivo. With a stable integrated mutated enhanced green fluorescent protein (EGFP) template in Chinese hamster ovary cells, up to 0.1% EGFP-positive cells were counted after transfection with b-oligonucleotides. The presence of EGFP protein in converted cells was demonstrated by anti-EGFP immunocytochemistry. Genomic sequencing of converted cells showed in 40% of the analysed clones the corrected wild-type codon, while 9.3% of the sequences showed a corrected wild-type sequence and an additional collateral mutation. Despite the stable corrected genomic locus, converted cells entered selective apoptosis after 3-6 days. The cell line Irs-1 that is deficient in the homologous recombination pathway showed a reduced frequency of boligonucleotide-induced site-specific sequence conversion. The reduced conversion rates in the mutant cell line could be partly rescued by complementation with XRCC2 cDNA.
Introduction
Repair of a mutated gene in a living cell is a challenge in biomedical research that would open attractive therapeutic strategies. Point mutations and small frame shifts account for many of the mutations that are causing monogenetic disorders. In the context of the broad spectrum of disease-linked genetic defects, an optimal therapeutic agent would be a small biological active molecule that enters the cell, finds a particular chromosomal localization, recognizes the mutation and induces specific repair/recombination at the site of the damage. If high efficacy and specificity of such an agent can be achieved, it could be used as an attractive platform technology for targeted genome modification.
The technique used most frequently for changing genetic information in vivo is based on homologous recombination between an extensive exogenous genomic sequence and homologous chromosomal loci. The technique is highly successful when combined with a selection system in a cell system like embryonic stem cells, but is not successful for targeted therapeutic gene alteration in somatic cells. [1] [2] [3] [4] Thus, alternative approaches have aimed to specifically target and alter chromosomal DNA with smaller structures. For targeting approaches without sequence constraint, short DNA fragments, 5 and modified or phosphothioate stabilized DNA oligonucleotides have been explored. [6] [7] [8] [9] Furthermore, bifunctional oligonucleotides that consist of a triple helix forming DNA recognition sequence, coupled either to DNA intercalating agents like psoralen [10] [11] [12] [13] [14] [15] [16] [17] [18] or to relatively short DNA domains that should serve as a template for the cell's own recombination or repair machinery, show some promise. [19] [20] [21] [22] Triple helix forming oligonucleotides (TFOs) recognize and require extensive polypurine stretches that are rare in the genome. 23 Attempts have been made to modify bases in the TFOs to tolerate pyrimidine interruptions [24] [25] [26] [27] [28] and to increase binding kinetics. 29 However, a general triple helix-based sequence recognition is not available.
Mechanisms underlying targeted gene correction are far from clear, but repair/recombination proteins including XPA hMSH2, and hRad51 have been implicated to be involved in targeted gene modification. 19, 20, 30, 31 hRad51 is the human homologue of the bacterial RecA protein that plays an important role in homologous recombination and recombinational repair. 32 Both RecA and hRad51 proteins bind readily to single-stranded (ss) DNA and promote DNA pairing and strand exchange with homologous duplex DNA in vitro. 33 However, it has been shown that the preferred substrate for Rad51-mediated homologous pairing is double-stranded (ds) DNA with ss DNA tails. 34 , 35 Here we demonstrate that direct in vivo gene modification can be achieved using a novel approach based on branched oligonucleotides (b-oligonucleotides). The b-oligonucleotides that are presented in this article consist of ds DNA with 5 0 ss DNA tails coupled together by a novel baseless deoxyribose (dR) branching monomer. In a Chinese hamster ovary (CHO) cell assay containing a stable integrated mutated enhanced green fluorescent protein (EGFP) reporter, specific correction of mutated EGFP to a functional wild-type sequence was observed after b-oligonucleotide administration in vivo. b-oligonucleotides gives a new tool for in vivo sequence alteration.
Results

Synthesis of branching monomers and branched DNA oligonucleotides
A branching monomer was synthesized to construct branched DNA oligonucleotides. The branching monomer allowed covalent linkage of a complementary DNA strand to a DNA oligonucleotide using a standard ABI 394 DNA/RNA synthesizer. As a branching point, novel protected dR branching units were synthesized as summarized in Figure 1a . The branching monomers allowed the synthesis of complementary branched oligonucleotides comprising of ss DNA sequences and ds DNA sequences covalently linked at a branching point. Two branching points could be incorporated into an oligonucleotide using a combination of products 5 and 6 in Figure 1a . However, in the present study, single branched oligonucleotides using the Fmoc-protected branching monomer were used. The first strand of the oligonucleotide incorporated product 5 and the last step of synthesis at this stage involved capping at the 5 0 end. The Fmoc group was then removed from the branching point (piperidine) and synthesis continued on the branching point (Figure 1b) .
Reporter assay
To obtain a simple and reproducible readout for targeted in vivo sequence alteration, a pEGFP-c1 plasmid under the control of the cytomegalovirus immediate-early enhancer (CMV IE) was mutated in two positions. Two silent diagnostic mutations were introduced in codon Gly34 (GGC-GGG) and in codon Gly41 (GGC-GGA). Subsequently, a functional amber stop codon was introduced in codon Lys42 (AAG-TAG). The derived plasmid was termed pmEGFP. To test whether the stop codon in pmEGFP would render EGFP nonfunctional, Figure 1 Synthesis scheme for branching monomer and b-oligonucleotide. (a) Synthesis scheme for branching monomer. Starting from deoxyribose (1), a branching point was incorporated at the 5 0 position and the monomer was protected with dimethoxytrityl (2) (standard oligonucleotide synthesis protection). The branching point was protected with either Fmoc (3), a base-labile protecting group, or MeNPOC (4), a photolabile protecting group. These were then converted to the branching monomers (5) and (6) as phosphoramidites. The stippled box indicates the branching monomer used in this study. (b) Synthesis scheme for branched oligonucleotides. The first strand is synthesized with incorporation of an Fmoc-protected dR branching monomer. After capping at the 5 0 end, the Fmoc group is removed form the dR branching monomer and synthesis continues from the branching point. Filled circles: nucleotides; open circle: dR branching monomer; arrows indicate direction of synthesis.
Branched oligonucleotides induce mutated EGFP reporter PA Olsen et al CHO-k1 cells were transfected with pmEGFP, and stable mEGFP-expressing cell lines were established by G418 selection. Expression of mEGFP was confirmed by reverse transcriptase (RT) PCR (not shown). When green fluorescence was measured by flow cytometry (FACS) in clonal mEGFP cell lines, no activity over background could be detected (not shown). The number of integrated copies of mEGFP in the clonal CHO cell line that was subsequently used (CHO-mEGFP) was calculated to be 2 by quantitative Southern blot analysis (data not shown).
Targeted in vivo correction using b-oligonucleotides CHO-mEGFP cells were transfected with DNA oligonucleotide constructs of varying length, design and terminal stabilization (Figure 2a ). To optimize transfection protocols, FuGENE 6 (Roche), LIPOFECTAMINE (Invitrogen), LIPOFECTAMINE 2000 (Invitrogen), ExGen 500 (linear polyethylenimine, PEI) (MBI Fermentas) and ethoxylated polyethylenimine (EPEI) (Gene Tools LLC, USA) were tested. For all oligonucleotide-based constructs, LIPOFECTAMINE 2000 or EPEI gave the highest numbers of positive cells and a low toxicity.
Two ss DNA oligonucleotides (S1 and S2) that correspond to the two strands of b-oligonucleotides, a ds looped oligonucleotide (L1) and a DNA/RNA chimeric circular oligonucleotide (C1), with sequences complementary to EGFP (containing a codon encoding for Lys42 instead of the mutated stop codon at position 42) were tested. Subsequently, various oligonucleotides containing an internal branching point (B1-B7) were used in the same assay. At 24 h after transfection of CHO-mEGFP cells with the constructs, fluorescent cells were counted by FACS analysis. To avoid false positives, the FACS gate was set to exclude weak fluorescent cells 
Structural alterations of b-oligonucleotides
To determine structural requirements in b-oligonucleotides that influence the number of converted cells, several structural features were altered ( Figure 2b and Table 1 ). B1-B4 have a circular ds DNA domain coupled to the branching point by a double hexaethyleneglycol spacer. B1-B3 have a gap towards the transcribed strand of the template, while B4 has a gap towards the nontranscribed strand. The noncircular constructs B6 and B7 have a ds domain that is linked to the branching point with a double hexaethyleneglycol spacer, while B5 has a single hexaethyleneglycol spacer. To stabilize the b-oligonucleotides to exonuclease degradation, 3 0 and/or 5 0 ends were protected with phosphothioate linkages and in B6 with aminopropyl groups. Interestingly, the b-oligonucleotide that led to highest conversion rates contained a 5 0 ss DNA overhang. To exclude the possibility that observed variations between different b-oligonucleotides were due to synthesis errors or differences in batches, several of the constructs were synthesized twice. In each case, transfections gave similar results.
As seen in Figure 2a , the circular constructs B1 and B4 showed extremely low conversion rates (0.012 and 0.0054%, respectively), while linear branched constructs (B5-B7) yielded higher conversion rates. Stabilization of the ends with phosphothioate linkages increased the conversion rates as seen in constructs B3 and B5-B7. Furthermore, b-oligonucleotides containing a smaller (27 bp) ds domain (B6-B7) yielded a higher number of converted cells than a construct containing a 33 bp stretch of ds DNA with a 3 0 ss overhang (B5). End protection of the B7 construct with aminopropyl groups decreased the correction frequency of the construct (B7 versus B6).
It was expected that a b-oligonucleotide containing a single mismatch with the chromosomal mEGFP target sequence should be the best template for targeted gene alteration. Every additional mismatch should reduce the efficiency of a hybridization between template and target. However, constructs that contain additional mismatches gave consistently higher conversion rates compared to constructs with only one single mismatch (eg B1 compared to B2). These could either be additional mismatches to the chromosomal template, and/or mismatches within the complementary ds sequence of the boligonucleotide ( Figure 2a ). Several combinations of mismatches in the b-oligonucleotides were tested (compare B1, B2 and B6, B7), including mismatches that are recognized by specific repair glycosylases. Nevertheless, no clear correlation between the type of the mismatches and the frequency of converted cells could be established. 
Construct Sequence
Scrambled ATGCAAAGTGCCGATAACATAACGATCTTTATAGAAACCATCGGCTTTTGCCGATGGTTTCTATAAAGATCGTTATGTCA CCACCGGCAAGC*T*G S1
T*G*C*CGGTGGTGCAGATGAACTTCAGGGTCAGCTTTCCGTA*G*G*T S2 A*C*C*TACGGAAAGCTGACCCTGAAGT*T*C*A L1 GATGCCACCTACGGAAAGCTGACCCTGAAG-
TGCCGGTGGTGCAGA5GAACTTCAGGGTCAGCTTTCCGTAGGTGGCATCG CCCTCCCCCTCG*C*C gatgccacctacgggaagctgaccctagagttc66 B6 8TGCCGGTGGTGCAGA5GAACTTCAGGGTCAGCTTTCCGTAG*G*T8 acctacgggaccctgaccctgaagttca66 B7 TGCCGGTGGTGCAGA5GAACTTCAGGGTCAGCTTGCCGTAG*G*T8 acctacgggaccctgaccctgaagttca66
ATGC: DNA residues (5 0 -3 0 ); AUGC: RNA residues (5 0 -3 0 ); atgc: DNA residues in the branching strand(5 0 -3 0 ); ATGCGatgc: DNA bases corresponding to the position of the mEGFP stop codon(codon 42); 5: baseless deoxyribose branched unit at the branching point; 6: hexaethyleneglycole spacer; 7: phosphate group; 8: aminopropyl group; * phosphothioate linkage.
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Converted cells produce functional EGFP and show corrected genomic sequence
To confirm that cells becoming fluorescent after boligonucleotide transfections produce a functional EGFP protein, anti-EGFP immunostaining was carried out on b-oligonucleotide-transfected CHO-mEGFP cells. As seen in Figure 3a , green fluorescent cells showed specific and strong anti-EGFP immunoreactivity demonstrating the presence of functional EGFP in the converted cells.
To analyse whether the presence of functional EGFP is due to a specific genomic alteration of the mEGFP template after b-oligonucleotide transfection, a PCRBranched oligonucleotides induce mutated EGFP reporter PA Olsen et al based sequence analysis was carried out. A CHOmEGFP2 cell line was established that contained only the stop codon at position 42 and the diagnostic mutation at codon 34 (not the diagnostic mutation at codon 41). This allows restriction enzyme digestion of the mEGFP2 sequence by NheI at the position of the stop codon (CGTAGC). However, if the sequence at the stop codon has been changed (eg to CGAAGC), NheI will not be able to cut at the site. Thus, PCR amplification combined with NheI digestion should allow to select for altered sequences (Figure 3b ). CHO-mEGFP2 cells were transfected with B7, and green cells were sorted by FACS after 24 h. A two-step PCR amplification following an NheI digestion and TA cloning of PCR products provided the template for the sequences shown in Figure 3c . All 32 sequenced PCR products contained the diagnostic mutation in codon 34, proving that the sequences shown were not amplified from a wildtype EGFP contamination.
As seen in Figure 3c , both predicted and unpredicted alterations have occurred in the mEGFP2 template. Of the amplified sequences 40.6% showed a stop codon (Stop42Lys, TAG-AAG) that has been correctly changed to the sequence encoded by the strand of the boligonucleotide B7 that is complementary to the nontranscribed strand of the mEGFP2 template. In addition, 9.3% of the amplified sequences have a corrected stop codon but also show additional flanking mutations that are not contained in the b-oligonucleotide. The remaining sequences still contained the unchanged stop codon, but showed a variety of flanking mutations that would render the NheI site unfunctional. Most of these mutations were in close proximity to the stop codon that was targeted with the introduced oligonucleotides. No mutations were found at the position of the branching point. The finding of mEGFP2 sequences without a corrected stop codon may be explained by the presence of two copies of the mEGFP2 in the genome of the transfected CHO-mEGFP2 cells and incomplete NheI digestion.
The observed collateral mutations in some of the sequences were followed up by measuring random mutagenesis of the hypoxanthine guanine phosphoribosyl transferase (HPRT) locus. After b-oligonucleotide transfection and 6-thioguanine selection, no significant difference in the number of colonies could be detected between mock (ss oligo) and b-oligonucleotide-treated cells (not shown).
Involvement of recombination pathways in b-oligonucleotide-directed mEGFP correction
Chinese hamster cell lines offer an attractive system since a substantial array of mutant cell lines exist that contain mutations or deletions in genes encoding for proteins that are central in genome maintenance pathways. 36 The Chinese hamster cell line Irs-1 is hypersensitive to genotoxic agents due to a deficiency of the XRCC2 gene. 37, 38 XRCC2 is a paralog of Rad51 and the proteins have been shown to be required for Rad51 focus formation 39 and homologous recombination repair. 40 The repair of site-specific ds break by homologous recombination is severely reduced in Irs-1 cells compared to the paternal V79-4 cell line. To compare the correction activities in the V79-4 and Irs-1 cell lines, a transient transfection protocol was selected. This was necessary to avoid differences between the cell lines in chromosomal integration of the reporter mEGFP gene that would make comparison of correction frequencies difficult. To normalize for possible differences in the transfection behaviour of the two cell lines, parallel transfections with a reporter plasmid (pEGFP-c1) were carried out and the FACS readout for pmEGFP/B7 targeted conversion was standardized against the FACS readout obtained with pEGFP-c1/scrambled DNA transfections. As a further control, cell death after transfection was assayed by PI staining. Cell death 24 h after transfection was generally low, ranging from 0.2 to 2.5%. As seen in Figure 4a , the Irs-1 cell line showed a significantly reduced number of converted cells when compared to the parental V79-4 cell line (5-fold reduction).
To determine whether conversion rates in the mutant cell lines could be influenced by altered rates of DNA degradation, test oligonucleotides were exposed to cell extracts from the respective cell lines. Extracts from the mutant Irs-1 cell line did not show degradation rates that were different from the parental V79-4 cell line ( Figure  4b ). Although this is an in vitro assay, the result indicates that the nuclease activities and DNA degradation rates appear not to diverge a lot between the two cell lines.
Complementation of the Irs-1 cell line
The involvement of XRCC2 in b-oligonucleotidemediated mEGFP gene conversion was supported by complementation experiments. The cell line Irs-1 was stably transfected with a bicistronic XRCC2-IRES-neomycin phosphotransferase construct (pIRESneo2-XRCC2), and put under G418 selective pressure. The G418 antibiotic exerts selective pressure of the entire IRES expression cassette, and it has been demonstrated that approximately 85% of the cells resistant to G418 also express XRCC2. 39 Following 14 days growth with G418 selection, Irs-1-IRES-XRCC2 cells were transfected with the pmEGFP/B7 mix and a correlation between XRCC2 complementation and the rate of converted cells could be established (Figure 4c ). Complemented Irs-1-IRES-XRCC2 cells showed a 3.6-fold increase of conversion rates compared to XRCC2-deficient Irs-1 cells. The mismatch combinations between the B7 oligonucleotide and the genomic template are indicated as red underlined letters in the box above the sequence. A total of 40.6% of the analysed sequences were reverted to the wild-type codon (AAG) without further mutations (n¼32); 9.3% were reverted to the wild-type sequence but contained an additional mutation at various positions; 18% still retained the mutated stop codon alone; while the remaining sequences contained a mutated stop codon and 1-2 additional mutations, unrelated to the B7 oligonucleotide template. No collateral mutations were found at the branching point or at the 3' and 5' ends of the b-oligonucleotide.
Apoptosis of green converted cells
In the mEGFP-based sequence alteration, b-oligonucleotides produced conversion at the genome level at frequencies that were highly reproducible. Despite repeated attempts, no viable clones of converted CHOmEGFP cells were obtained with either branched or nonbranched oligonucleotides. In order to monitor the fate of the green converted cells, Annexin V assays were carried out. Annexin V detects increased appearance of phosphatidylserine on the outer membrane leaflet on apoptotic cells, and is used as an early marker of apoptosis. With this assay, 70% of the converted cells were classified to be apoptotic or necrotic/late apoptotic 6 days after transfection. For transfected, nonconverted cells, the value was 20% similar to untransfected cells (Figure 5a ). In addition, TUNEL assay was carried out on green converted cells. This apoptosis assay adds labelled nucleotides to free 3 0 DNA ends. As seen in Figure 5b , EGFP-expressing converted cells entered apoptosis when stained 3 days after transfection, but surrounding nonexpressing cells were negative by TUNEL staining. The TUNEL assay could be influenced by the presence of transfected oligonucleotides. However, we did not detect general background staining. Furthermore, we excluded that the presence of the EGFP protein it self can account for the observed apoptosis by expressing wild type EGFP in CHO-k1 cells. Therefore, we conclude that the observed apoptosis is coupled to the targeted sequence alteration rather than to general toxicity.
Discussion
Evidence suggests that the use of small oligonucleotides for site-specific genome alteration in living cells -albeit at low frequency -is a feasible concept. However, difficulties with the considerable variations between rates of targeted conversion in the published record, uncertainty about collateral and unspecific background mutations, and severe sequence constrains with some of the oligonucleotide-based structures keep the approach hitherto well below the threshold for potential applications.
In the present study, a new structure is presented that can provoke targeted gene alteration in vivo. The observed conversion rates show low variation between experiments and are significantly higher than the nonbranched structures that were tested. The effect of b-oligonucleotides was tested on a standardized assay based on a mutated EGFP template; however, boligonucleotides should in principle be able to be designed without obvious sequence constraints for any given genomic sequence.
The mechanisms that are required for the observed sequence conversion are still unclear; however, some aspects are becoming evident. (i) In serum, b-oligonucleotides do not show an increased stability against DNase attacks when compared to unbranched simple oligonucleotides (not shown). Therefore, the general structure of a covalently linked ds and ss domain may offer advantages. In this context, it is noteworthy that the preferred DNA substrate for Rad51 is ss tailed ds DNA rather than ss DNA. 34 Also an increased stability against helicase activity may offer an explanation, but remains to be investigated.
(ii) In the presented sequence data all corrected sequences are derived from the b-oligonucleotide strand that is complementary to the nontranscribed chromosomal mEGFP2 template. In addition, only the ss construct targeting the nontranscribed template strand (S1) gave a 
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PA Olsen et al measurable mEGFP correction. These data are compatible with the finding of Liu et al, 41 which shows a seven-to eight-fold increase in in vitro oligonucleotide-based sitespecific mutagenesis at the nontranscribed strand. (iii) The finding that oligonucleotides of such short structure are able to alter site-specific genomic sequences in vivo remains surprising. In contrast to bifunctional oligonucleotides that contain an active (triple helix based) targeting domain, boligonucleotides should not be able to recognize a ds DNA template by physical interaction. Instead, they would require cellular machinery like the cellular recombination complex for target recognition.
The reduction of b-oligonucleotide-mediated conversion frequencies seen in the XRCC2-deficient Irs-1 cell line argues in favour of the involvement of homologous recombination. Albeit the extra chromosomal approach that was used in the present study simplifies the invasion step, the dependence between sequence conversion and XRCC2 demonstrates the importance of the homologous recombination machinery in the process. XRCC2 has been shown to be necessary for homologous recombination repair 40 and is required for Rad51 focus formation that catalyses homologous DNA strand exchange. 39 The importance of Rad51 for oligonucleotide-induced gene conversion in cell lines has also been documented for both short DNA fragments 8 and bifunctional, triple helix containing oligonucleotides. 20 b-oligonucleotides that contain more than one mismatch produce consistently higher sequence conversion rates than b-oligonucleotides that contain only a single mismatch. Mismatches between homologous strands strongly reduce the rates of homologous recombination. Additional mismatches however may make the site more visible to the highly efficient cellular repair machinery; they may also dissolve the ds domain into free ss ends and thus provide a better substrate for ss binding proteins including Rad51.
Despite the relatively high rates of in vivo conversion seen after b-oligonucleotide transfection the approach leads to cell survival problems of the converted cells. In our hands, apoptosis has been observed in converted cells after transfection with both unbranched oligonucleotides and b-oligonucleotides. It has been demonstrated that transfection of cells with ss DNA induces G1 arrest and apoptois. [42] [43] [44] It is also known that cells stop replicating and enter apoptosis when unrepaired ds breaks accumulate. 45 Furthermore, strand breaks can be induced if the replication fork is stalled because of a block in template DNA. 46 Whether the apoptosis observed in our experiments is a general problem associated with the presence of large amounts of oligonucleotides in cells, whether it is a more specific process related to cells that have undergone sequence conversion and whether any of the above mechanisms account for the observed selective apoptosis is currently under investigation. Given that the observed apoptosis appears at 4-6 days after transfection, it will not have influence on the general toxicity parameters that were measured 1 day after transfection. Branched oligonucleotides induce mutated EGFP reporter PA Olsen et al Taken together, the present work shows that boligonucleotides can induce in vivo targeted sequence alteration on a genome level in a cell culture system at higher levels than ss DNA oligonucleotides or looped ds DNA oligonucleotides of similar sequence. It also provides evidence for one of the underlying cellular pathways by identifying XRCC2 as a factor that influences conversion rates. Despite the obvious obstacles, b-oligonucleotides should serve as a platform for further development towards a strategy for small molecule-based genome alteration.
Materials and methods
Synthesis of branching monomer 3,5-O-ditoluoyl-1-chloro-2-deoxy-D-ribose was prepared from 2-deoxy-D-ribose in 77% yield. Displacement of the chloro group with TFA-protected aminohexanol gave an anomeric mixture in 85% yield. Removal of the toluoyl protecting groups and dimethoxytritylation at the 5 position gave an anomeric mixture in approximately a 1:1 ratio. These were easily separated by column chromatography on silica gel. The b-anomer was deprotected to give a free amine, and coupled with aminododecanoic acid (95% yield). The side chain free hydroxyl group was protected with either Fmoc or MeNPOC followed by phosphitylation to give the cyanoethylphosphoramidites 5 and 6 in Figure 1a respectively.
Synthesis of branched oligonucleotides
The main part of the oligonucleotide, including the protected deoxyribose branching unit, was synthesized ''DMT off, manual'' using normal phosphoramidite chemistry on an ABI 394 DNA/RNA synthesizer. The column was removed from the synthesizer and capped manually using cap A (acetic anhydride/pyridine/ THF)/cap B (1-methylimidazole) 1:1 for 5 min. The resin was washed (MeCN) and dried (Ar). The branching monomer protection was removed from the dR unit with 20% piperidine/DMF (10 min) (Fmoc) or by photolysis (366 nm) and the resin washed (DMF/MeCN 1:1, MeCN), dried (Ar) and replaced on the synthesizer. The hexaethyleneglycol spacer unit(s) was added at this point followed by the branched DNA strand ending in a phosphate residue. Deprotection was carried out at 551C overnight (or 701C for 2.5 h) and purified by FPLC. All oligonucleotides and DNA/RNA chimeras were synthesized by Oswel/Eurogentech (Southampton, UK). The sequences and design of the different constructs are listed in Table 1 .
Plasmids pmEGFP was made by introducing a silent diagnostic mutation in codon Gly34 (GGC-GGG) and codon Gly41 (GGC-GGA), and a functional stop codon at Lys42 (AAG-TAG) in the pEGFP-c1 plasmid (Clonetech), using the Quickchange mutagenesis kit (Stratagene). The pmEGFP2 plasmid that was used for PCR analysis and sequencing did not contain the silent mutation in codon Gly41. pIRESneo2-XRCC2 was a gift from J Thacker (Medical Research Council, UK).
Cell culture and cell line construction
The cell lines CHO-k1 (CCL-61) and V79-4 (CCL-93) were purchased from American Type Culture Collection (ATCC). The Irs-1 cell line was a gift from J Thacker. All cell lines were grown in Ham F-12 media (GIBCOt) supplemented with 5% fetal bovine serum (FBS), 100 U/ ml penicillin and 100 mg/ml streptomycin (BioWhittaker).
The CHO-mEGFP cell line was created by transfection with pmEGFP using FuGENE 6 (Roche Diagnostics) as recommended by the manufacturer (2 mg plasmid DNA, 4 ml FuGENE into 2 ml growth media per well in six-well dishes). Colonies were isolated after 10-14 days in culture under 0.8 mg/ml G418 (GIBCOt) selection. Isolated stable clones were maintained in growth media supplemented with 0.4 mg/ml G418. Clones were assayed for mEGFP expression by RT-PCR. Briefly, total mRNA was isolated from 10 6 cells using the RNAqueoust-4PCR Kit (Ambion, Austin, TX, USA), and RT-PCR was carried out using the RETROscriptt First Strand Synthesis Kit (Ambion). PCR cycle conditions were 941C/30 s, 591C/30 s and 721C/45 s for 30 cycles with primers P1 and P2 (P1: CCCATCCTGGTC-GAGCTGGA; P2: CGCGCTTCTCGTTGGGGTCT).
The cell line Irs-1-IRES-XRCC2 was made by transfecting (FuGENE 6) cell line Irs-1 with the pIRESneo2-XRCC2 plasmids. At 2 days after transfection, cells were exposed to 1.3 mg/ml G418. The cells were allowed to grow for 14 days in their selective media before they were used in experiments.
In vivo sequence conversion assay
Oligonucleotide and b-oligonucleotide transfection was performed using LIPOFECTAMINEt 2000 (LF2000) (Invitrogen) according to the manufacturer's suggestions. Briefly, 4.5 mg oligonucleotide and 10 ml LF2000 were diluted in 0.5 ml Opti-MEM s I (GIBCOt) and applied to cells in 2 ml growth media (with FBS, without antibiotics) per well in six-well plates. The transfection mixture was left on the cells for 1 h before it was replaced with fresh growth media. Cells were assayed for gene conversion 24 h after transfection.
Episomal gene conversion assay
In all, 2 mg pmEGFP plasmid DNA and 2 mg oligonucleotide were mixed in sterile water in a total volume of 20 ml. The mixture was heated to 901C for 2 min and slowly allowed to cool to room temperature. A total of 1.3 Â 10 5 cells per well in six well plates were transfected with the plasmid/oligonucleotide mixture using 5 ml FuGENE 6 per well. The transfection mixture was left on the cells until they were assayed for green fluorescence (24 h) by FACS.
Immunocytochemistry
EGFP immunostaining was performed as previously described. 47 Anti-GFP (A-11120, Molecular Probes) was used as primary antibody (1.67 mg/ml concentration) and Alexat594 anti-mouse IgG (A-11005, Molecular Probes) was used as secondary antibody (1/500 dilution).
Microscopy and FACS analysis
EGFP immunocytochemistry imaging was carried out 24 h post-transfection with an inverted fluorescence microscope (Leica DM IRB) equipped with a Photo- 
Sequencing of genomic DNA
CHO-mEGFP2 cells transfected with the construct B7 were selected by FACS 28 h after transfection, washed once with PBS, resuspended in 2 ml proteinase K buffer (0.5% tween 20, 100 mg/ml proteinase K, in 1 Â PCR buffer), and incubated at 561C for 45 min and at 801C for 20 min. The DNA was used for a nested PCR amplification (Figure 3b ). In the first amplification, primers P1 and P2 generated a 610 bp PCR product (941C/30 s, 591C/ 30 s, 721C/45 s for 30 cycles). The product was purified (High pure PCR product purification up kit, Roche) and digested for 2 h with NheI (New England Biolabs) to eliminate unconverted mEGFP2 sequences. In the subsequent amplification, primers P1 and P3 (P3: GTCGATGCCCTTCAGCTCGA) generated a 350 bp product (941C/45 s, 641C/30 s, 721C/60 s for 30 cycles). The 350 bp fragment was TA cloned, and transformed into the pCR s -II s vector (TOPO TA cloning s kit, Invitrogen). Individual clones were isolated (QIAprep Spin Miniprep Kit, QIAGEN) and subjected to sequencing on a Beckman CEQ8000 Genetic Analysis System.
DNA degradation assay in cell-free extracts
Cell-free extracts from the V79-4 and Irs-1 cell lines were prepared by resuspending 1.5 Â 10 7 cells in 250 ml extraction buffer (50 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 mM EDTA, 10% glycerol, freshly added 5 mM DTT and protease inhibitor cocktail (1:250 dilution) (Sigma P8340)), sonicated with eight pulses (1 s each) and centrifuged at 13 000 rpm for 45 min on a microcentrifuge. The total protein (TP) concentration was determined by the Bio-Rad protein assay (Bio-Rad) and all cell extracts were adjusted to the same TP concentration with extraction buffer. A 38-mer ss DNA primer was labelled at the 5 0 terminus by T4 polynucleotide kinase (New England Biolabs) and [g- were mixed with 32 P-labelled primer and water to a final TP of 0.25 mg/ml in a total volume of 50 ml and incubated at 371C. At the indicated time points (0-0.5-1.0-1.5-2.0 h), 5 ml was removed and mixed with 5 ml denaturating loading buffer (80% formamide, 10 mM NaOH, 1 mM EDTA, 0.1% xylene cyanol, 0.1% bromophenol blue) and kept at À701C until analysis. The degradation was measured by analysing the harvested aliquots on a de-naturating polyacrylamide gel electrophoresis (PAGE) (15% gel, 8 M urea). The bands were detected and quantified on a Molecular Dynamics Phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA).
Annexin V assay
CHO-mEGFP cells were transfected with the B7 construct in six-well plates. At the indicated time points (after transfection), cells were gently trypsinized (0.5 Â trypsin-EDTA solution) and stained with an AnnexinV-Alexa350 (Molecular Probes) conjugate according to the manufacturer's recommendations. PI was included as a live/dead stain. In the three colour FACS analysis, green cells and nongreen cells were gated into separate dotplots in which Alexa350 versus PI fluorescence was plotted. Thus, apoptotic cells were AnnexinV-Alexa350 positive and necrotic/late apoptotic cells were both AnnexinV-Alexa350 and PI positive.
TUNEL assay
The In situ Cell Death Detection Kit Fluorescein (TUNEL staining) (Roche) was used to label DNA strand breaks in CHO-mEGFP cells, 3 days after transfection with the B7 construct. In order to be capable of distinguishing EGFP fluorescence (converted cells) from fluorescein fluorescence (TUNEL-positive cells), cells were stained with an anti-fluorescein-Alexa594 antibody (A-11091, Molecular Probes). After TUNEL staining, cells were washed in PBS, blocked (5% BSA, 5% goat serum) and incubated with anti-fluorescein-Alexa594 (4 mg/ml) for 1 h, washed in PBS and analysed by fluorescence microscopy. Binding of anti-fluorescein-Alexa594 to fluorescein will quench fluorescein emission and transform it into red fluorescence, consequently, TUNEL-positive apoptotic cells will show red fluorescence.
